A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
← catalyst calendarNCT06012240 · readout ≤ 1,350 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,500estimated
Sites
283
Countries
Argentina, Australia, Belgium +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-11 | actual | When the study began enrolling |
| Primary completion | Apr 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Upadacitinib — also filed as Rinvoq, ABT-494
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20
measured Week 24
Number of Participants with Adverse Events (AEs)
measured Up to approximately 164 weeks
Publications
- PMID 42584887 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed